Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Investigation of Psychoactive Medications: Challenges and a Practical and Scalable New Path

Author(s): Dekel Taliaz* and Alessandro Serretti

Volume 22, Issue 9, 2023

Published on: 29 August, 2022

Page: [1267 - 1274] Pages: 8

DOI: 10.2174/1871527321666220628103843

Abstract

In the last two decades the validity of clinical trials in psychiatry has been subjected to discussion. The most accepted clinical study method in the medical area, i.e. the randomized controlled trial (RCT), faces significant problems when applied to the psychiatric field. One of the causes for this scenario is the strict participant inclusion and exclusion criteria that may not represent the real world. The inconsistency of the different endpoint parameters that are used in the field is another cause. We think that psychiatric RCTs’ challenges, together with the underlying complexity of psychiatry, lead to a problematic clinical practice. Psychoactive substances are currently routinely tested outside of a formal clinical trial environment. Off-label psychoactive drugs are commonly prescribed, and other substances, such as herbal remedies, are also regularly consumed. These real-life experiments can teach us useful lessons. Real-world data (RWD) includes information about heterogeneous patient populations, and it can be measured with standardized parameters. Collecting RWD can also address the need for systematically documenting and sharing case reports’ outcomes. We suggest using digital tools to capture objective and continuous behavioral data from patients passively. New conclusions will be constantly drawn, possibly allowing more personalized treatment outcomes. The relevant nextgeneration decision support tools are already available.

Keywords: Real-world data, clinical trials, off-label, digital tools, standardized parameters, personalized psychiatry.

Next »
[1]
Guze SB. Nature of psychiatric illness: Why psychiatry is a branch of medicine. Compr Psychiatry 1978; 19(4): 295-307.
[http://dx.doi.org/10.1016/0010-440X(78)90012-3] [PMID: 679664]
[2]
Lipowski ZJ. Psychiatry: Mindless or brainless, both or neither? Can J Psychiatry 1989; 34(3): 249-54.
[http://dx.doi.org/10.1177/070674378903400318] [PMID: 2637674]
[3]
Bracken P, Thomas P, Timimi S, et al. Psychiatry beyond the current paradigm. Br J Psychiatry 2012; 201(6): 430-4.
[http://dx.doi.org/10.1192/bjp.bp.112.109447] [PMID: 23209088]
[4]
Surís A, Holliday R, North CS. The evolution of the classification of psychiatric disorders. Behav Sci (Basel) 2016; 6(1): 5.
[http://dx.doi.org/10.3390/bs6010005] [PMID: 26797641]
[5]
Kendell RE. The role of diagnosis in psychiatry. Blackwell Scientific Publications 1975.
[6]
Fried EI, Nesse RM. Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study. J Affect Disord 2015; 172: 96-102.
[http://dx.doi.org/10.1016/j.jad.2014.10.010] [PMID: 25451401]
[7]
Zimmerman M, Ellison W, Young D, Chelminski I, Dalrymple K. How many different ways do patients meet the diagnostic criteria for major depressive disorder? Compr Psychiatry 2015; 56: 29-34.
[http://dx.doi.org/10.1016/j.comppsych.2014.09.007] [PMID: 25266848]
[8]
Hyman SE. The diagnosis of mental disorders: The problem of reification. Annu Rev Clin Psychol 2010; 6(1): 155-79.
[http://dx.doi.org/10.1146/annurev.clinpsy.3.022806.091532] [PMID: 17716032]
[9]
Perugi G, Barbuti M. There are no patients without comorbidity. J Eur Coll Neuropsychopharmacol 2021; 50: 104-6.
[http://dx.doi.org/10.1016/j.euroneuro.2021.05.002] [PMID: 34077858]
[10]
Widiger TA. Categorical versus dimensional classification: Implications from and for research. J Pers Disord 1992; 6(4): 287-300.
[http://dx.doi.org/10.1521/pedi.1992.6.4.287]
[11]
Widiger TA, Trull TJ. Plate tectonics in the classification of personality disorder: Shifting to a dimensional model. Am Psychol 2007; 62(2): 71-83.
[http://dx.doi.org/10.1037/0003-066X.62.2.71] [PMID: 17324033]
[12]
Livesley WJ, Jackson DN, Schroeder ML. Factorial structure of traits delineating personality disorders in clinical and general population samples. J Abnorm Psychol 1992; 101(3): 432-40.
[http://dx.doi.org/10.1037/0021-843X.101.3.432] [PMID: 1500600]
[13]
Goldberg D. A dimensional model for common mental disorders. Br J Psychiatry Suppl 1996; 168(30): 44-9.
[http://dx.doi.org/10.1192/S0007125000298401] [PMID: 8864148]
[14]
Kotov R, Krueger RF, Watson D, et al. The hierarchical taxonomy of psychopathology (HiTOP): A dimensional alternative to traditional nosologies. J Abnorm Psychol 2017; 126(4): 454-77.
[http://dx.doi.org/10.1037/abn0000258] [PMID: 28333488]
[15]
Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: Variable, substantial, and growing. JAMA 2002; 287(14): 1840-7.
[http://dx.doi.org/10.1001/jama.287.14.1840] [PMID: 11939870]
[16]
Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72(3): 115-27.
[http://dx.doi.org/10.1159/000069738] [PMID: 12707478]
[17]
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Focus Am Psychiatr Publ 2018; 16(4): 420-9.
[http://dx.doi.org/10.1176/appi.focus.16407] [PMID: 32021580]
[18]
PHARMA Biopharmaceutical industry-sponsored clinical trials. In: Impact on State Economies. Battelle 2015.
[19]
Robinson DS, Rickels K. Concerns about clinical drug trials. J Clin Psychopharmacol 2000; 20(6): 593-6.
[http://dx.doi.org/10.1097/00004714-200012000-00001] [PMID: 11106129]
[20]
Sarter M, Tricklebank M. Revitalizing psychiatric drug discovery. Nat Rev Drug Discov 2012; 11(6): 423-4.
[http://dx.doi.org/10.1038/nrd3755] [PMID: 22653200]
[21]
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23(1): 56-62.
[http://dx.doi.org/10.1136/jnnp.23.1.56] [PMID: 14399272]
[22]
Fried EI. Moving forward: How depression heterogeneity hinders progress in treatment and research. Expert Rev Neurother 2017; 17(5): 423-5.
[http://dx.doi.org/10.1080/14737175.2017.1307737] [PMID: 28293960]
[23]
Junod SW. FDA and clinical drug trials: A short history. Quick Guide Clin Trials 2008; 2008: 25-55.
[24]
Everitt BS, Wessely S. Clinical trials in psychiatry. Hoboken, New Jersey: John Wiley & Sons 2008.
[25]
March JS, Silva SG, Compton S, Shapiro M, Califf R, Krishnan R. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005; 162(5): 836-46.
[http://dx.doi.org/10.1176/appi.ajp.162.5.836] [PMID: 15863782]
[26]
Loftus J, Scott J, Vorspan F, et al. Psychiatric comorbidities in bipolar disorders: An examination of the prevalence and chronology of onset according to sex and bipolar subtype. J Affect Disord 2020; 267: 258-63.
[http://dx.doi.org/10.1016/j.jad.2020.02.035] [PMID: 32217226]
[27]
Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005; 62(6): 617-27.
[http://dx.doi.org/10.1001/archpsyc.62.6.617] [PMID: 15939839]
[28]
Licht RW, Gouliaev G, Vestergaard P, Frydenberg M. Generalisability of results from randomised drug trials. A trial on antimanic treatment. Br J Psychiatry 1997; 170(3): 264-7.
[http://dx.doi.org/10.1192/bjp.170.3.264] [PMID: 9229034]
[29]
Zimmerman M, Posternak MA, Chelminski I. Symptom severity and exclusion from antidepressant efficacy trials. J Clin Psychopharmacol 2002; 22(6): 610-4.
[http://dx.doi.org/10.1097/00004714-200212000-00011] [PMID: 12454561]
[30]
Woods SW, Ziedonis DM, Sernyak MJ, Diaz E, Rosenheck RA. Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. Psychiatr Serv 2000; 51(1): 79-84.
[http://dx.doi.org/10.1176/ps.51.1.79] [PMID: 10647137]
[31]
Santor DA, Gregus M, Welch A. Eight decades of measurement in depression. Measurement 2006; 4(3): 135-55.
[http://dx.doi.org/10.1207/s15366359mea0403_1]
[32]
Fried EI. The 52 symptoms of major depression: Lack of content overlap among seven common depression scales. J Affect Disord 2017; 208: 191-7.
[http://dx.doi.org/10.1016/j.jad.2016.10.019] [PMID: 27792962]
[33]
Demyttenaere K, Desaiah D, Petit C, Croenlein J, Brecht S. Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder. Prim Care Companion J Clin Psychiatry 2009; 11(1): 8-15.
[http://dx.doi.org/10.4088/PCC.08m00670] [PMID: 19333404]
[34]
Mark TL, Levit KR, Buck JA. Datapoints: Psychotropic drug prescriptions by medical specialty. Psychiatr Serv 2009; 60(9): 1167-7.
[http://dx.doi.org/10.1176/ps.2009.60.9.1167] [PMID: 19723729]
[35]
Boesen K, Gøtzsche PC, Ioannidis JPA. EMA and FDA psychiatric drug trial guidelines: Assessment of guideline development and trial design recommendations. Epidemiol Psychiatr Sci 2021; 30: e35.
[http://dx.doi.org/10.1017/S2045796021000147] [PMID: 33926608]
[36]
Erhel F, Scanff A, Naudet F. The evidence base for psychotropic drugs approved by the European Medicines Agency: A meta-assessment of all European Public Assessment Reports. Epidemiol Psychiatr Sci 2020; 29: e120.
[http://dx.doi.org/10.1017/S2045796020000359] [PMID: 32336312]
[37]
Kharadi D, Patel K, Rana D, Patel V. Off-label drug use in psychiatry outpatient department: A prospective study at a tertiary care teaching hospital. J Basic Clin Pharm 2015; 6(2): 45-9.
[http://dx.doi.org/10.4103/0976-0105.152090] [PMID: 25767363]
[38]
Vijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One 2018; 13(7): e0198363.
[http://dx.doi.org/10.1371/journal.pone.0198363] [PMID: 30024873]
[39]
Braüner JV, Johansen LM, Roesbjerg T, Pagsberg AK. Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry. J Clin Psychopharmacol 2016; 36(5): 500-7.
[http://dx.doi.org/10.1097/JCP.0000000000000559] [PMID: 27529772]
[40]
Philip NS, Mello K, Carpenter LL, Tyrka AR, Price LH. Patterns of quetiapine use in psychiatric inpatients: An examination of off-label use. Ann Clin Psychiatry 2008; 20(1): 15-20.
[http://dx.doi.org/10.1080/10401230701866870] [PMID: 18297582]
[41]
Lowe-Ponsford FL, Baldwin DS. Off-label prescribing by psychiatrists. Psychiatr Bull 2000; 24(11): 415-7.
[http://dx.doi.org/10.1192/pb.24.11.415]
[42]
Devulapalli KK, Nasrallah HA. An analysis of the high psychotropic off-label use in psychiatric disorders The majority of psychiatric diagnoses have no approved drug. Asian J Psychiatr 2009; 2(1): 29-36.
[http://dx.doi.org/10.1016/j.ajp.2009.01.005] [PMID: 23051015]
[43]
Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001. J Clin Psychiatry 2006; 67(6): 972-82.
[http://dx.doi.org/10.4088/JCP.v67n0615] [PMID: 16848658]
[44]
Hálfdánarson Ó, Zoëga H, Aagaard L, et al. International trends in antipsychotic use: A study in 16 countries, 2005-2014. Eur Neuropsychopharmacol 2017; 27(10): 1064-76.
[http://dx.doi.org/10.1016/j.euroneuro.2017.07.001] [PMID: 28755801]
[45]
Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011; 20(2): 177-84.
[http://dx.doi.org/10.1002/pds.2082] [PMID: 21254289]
[46]
Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166(9): 1021-6.
[http://dx.doi.org/10.1001/archinte.166.9.1021] [PMID: 16682577]
[47]
Carton L, Cottencin O, Lapeyre-Mestre M, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: A systematic review of recent prescription trends. Curr Pharm Des 2015; 21(23): 3280-97.
[http://dx.doi.org/10.2174/1381612821666150619092903] [PMID: 26088115]
[48]
Kamble P, Sherer J, Chen H, Aparasu R. Off-label use of second-generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv 2010; 61(2): 130-6.
[http://dx.doi.org/10.1176/ps.2010.61.2.130] [PMID: 20123817]
[49]
Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993; 328(4): 246-52.
[http://dx.doi.org/10.1056/NEJM199301283280406] [PMID: 8418405]
[50]
Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 1998; 280(18): 1569-75.
[http://dx.doi.org/10.1001/jama.280.18.1569] [PMID: 9820257]
[51]
Ravven SE, Zimmerman MB, Schultz SK, Wallace RB. 12-month herbal medicine use for mental health from the national Comorbidity Survey Replication (NCS-R). Ann Clin Psychiatry 2011; 23(2): 83-94.
[PMID: 21547268]
[52]
Lopez-Quintero C, Warren T, Falise A, Sharma V, Bares C, Oshri A. Prevalence and drug use correlates of extra-medical use of prescription medications for sleep among adults in the United States: Results of the 2015-2018 national survey on drug use and health. Pharmacol Biochem Behav 2021; 204: 173169.
[http://dx.doi.org/10.1016/j.pbb.2021.173169] [PMID: 33684453]
[53]
Parker MA, Anthony JC. Epidemiological evidence on extra-medical use of prescription pain relievers: Transitions from newly incident use to dependence among 12-21 year olds in the United States using meta-analysis, 2002-13. PeerJ 2015; 3: e1340.
[http://dx.doi.org/10.7717/peerj.1340] [PMID: 26623183]
[54]
Monteith S, Glenn T. Searching online to buy commonly prescribed psychiatric drugs. Psychiatry Res 2018; 260: 248-54.
[http://dx.doi.org/10.1016/j.psychres.2017.11.037] [PMID: 29220682]
[55]
Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC. Epidemiological patterns of extra-medical drug use in the United States: Evidence from the National Comorbidity Survey Replication, 2001-2003. Drug Alcohol Depend 2007; 90(2-3): 210-23.
[http://dx.doi.org/10.1016/j.drugalcdep.2007.03.007] [PMID: 17481828]
[56]
Ventegodt S, Merrick J. Psychoactive drugs and quality of life. Sci World J 2003; 3: 694-706.
[http://dx.doi.org/10.1100/tsw.2003.57] [PMID: 12941969]
[57]
Corazza O, Demetrovics Z, van den Brink W, Schifano F. ‘Legal highs’ an inappropriate term for ‘novel psychoactive drugs’ in drug prevention and scientific debate. Int J Drug Policy 2013; 24(1): 82-3.
[http://dx.doi.org/10.1016/j.drugpo.2012.06.005] [PMID: 22883544]
[58]
Valente MJ, Guedes de Pinho P, de Lourdes Bastos M, Carvalho F, Carvalho M. Khat and synthetic cathinones: A review. Arch Toxicol 2014; 88(1): 15-45.
[http://dx.doi.org/10.1007/s00204-013-1163-9] [PMID: 24317389]
[59]
Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA 2011; 306(12): 1359-69.
[http://dx.doi.org/10.1001/jama.2011.1360] [PMID: 21954480]
[60]
Rinke ML, Bundy DG, Shore AD, Colantuoni E, Morlock LL, Miller MR. Pediatric antidepressant medication errors in a national error reporting database. J Dev Behav Pediatr 2010; 31(2): 129-36.
[http://dx.doi.org/10.1097/DBP.0b013e3181ce6509] [PMID: 20110823]
[61]
Khan A, Fahl Mar K, Faucett J, Khan Schilling S, Brown WA. Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013. World Psychiatry 2017; 16(2): 181-92.
[http://dx.doi.org/10.1002/wps.20421] [PMID: 28498591]
[62]
Cipriani A, Salanti G, Furukawa TA, et al. Antidepressants might work for people with major depression: Where do we go from here? Lancet Psychiatry 2018; 5(6): 461-3.
[http://dx.doi.org/10.1016/S2215-0366(18)30133-0] [PMID: 29628364]
[63]
Fabbri C, Kasper S, Zohar J, et al. Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. Prog Neuropsychopharmacol Biol Psychiatry 2021; 104: 110050.
[http://dx.doi.org/10.1016/j.pnpbp.2020.110050] [PMID: 32738352]
[64]
Fabbri C, Pain O, Hagenaars SP, Lewis CM, Serretti A. Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. Neuropsychopharmacology 2021; 46(10): 1821-9.
[http://dx.doi.org/10.1038/s41386-021-01059-6] [PMID: 34158615]
[65]
Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: New indications and new populations. J Psychiatr Res 2001; 35(3): 187-91.
[http://dx.doi.org/10.1016/S0022-3956(01)00020-6] [PMID: 11461715]
[66]
Zhang Z-J, Kang W-H, Li Q, Tan Q-R. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) for mood disorders: Double-blind, placebo-controlled studies. J Psychiatr Res 2007; 41(10): 828-36.
[http://dx.doi.org/10.1016/j.jpsychires.2006.08.002] [PMID: 17010995]
[67]
Sayyah M, Boostani H, Pakseresht S, Malaieri A. Efficacy of aqueous extract of Echium amoenum in treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(8): 1513-6.
[http://dx.doi.org/10.1016/j.pnpbp.2009.08.021] [PMID: 19737592]
[68]
Amsterdam JD, Li Y, Soeller I, Rockwell K, Mao JJ, Shults J. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol 2009; 29(4): 378-82.
[http://dx.doi.org/10.1097/JCP.0b013e3181ac935c] [PMID: 19593179]
[69]
Movafegh A, Alizadeh R, Hajimohamadi F, Esfehani F, Nejatfar M. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: A double-blind, placebo-controlled study. Anesth Analg 2008; 106(6): 1728-32.
[http://dx.doi.org/10.1213/ane.0b013e318172c3f9] [PMID: 18499602]
[70]
Krcevski-Skvarc N, Wells C, Häuser W. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European pain federation. Eur J Pain 2018; 22(3): 440-54.
[http://dx.doi.org/10.1002/ejp.1147] [PMID: 29134767]
[71]
FDA Nasal spray medication for treatment-resistant depression. 2020. Available from : https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
[72]
Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012; 87(10): 982-90.
[http://dx.doi.org/10.1016/j.mayocp.2012.04.017] [PMID: 22877654]
[73]
Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc 2010; 85(3): S3-S14.
[http://dx.doi.org/10.4065/mcp.2009.0649] [PMID: 20194146]
[74]
Fineberg NA, Hollander E, Pallanti S, et al. Clinical advances in obsessive-compulsive disorder: A position statement by the international college of obsessive-compulsive spectrum disorders. Int Clin Psychopharmacol 2020; 35(4): 173-93.
[http://dx.doi.org/10.1097/YIC.0000000000000314] [PMID: 32433254]
[75]
Jagesar RR, Roozen MC, van der Heijden I, et al. Digital phenotyping and the COVID-19 pandemic: Capturing behavioral change in patients with psychiatric disorders. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2021; 42: 115-20.
[http://dx.doi.org/10.1016/j.euroneuro.2020.11.012] [PMID: 33298386]
[76]
Mundt JC, Vogel AP, Feltner DE, Lenderking WR. Vocal acoustic biomarkers of depression severity and treatment response. Biol Psychiatry 2012; 72(7): 580-7.
[http://dx.doi.org/10.1016/j.biopsych.2012.03.015] [PMID: 22541039]
[77]
Mundt JC, Snyder PJ, Cannizzaro MS, Chappie K, Geralts DS. Voice acoustic measures of depression severity and treatment response collected via interactive voice response (IVR) technology. J Neurolinguist 2007; 20(1): 50-64.
[http://dx.doi.org/10.1016/j.jneuroling.2006.04.001] [PMID: 21253440]
[78]
Tonon AC, Fuchs DFP, Barbosa Gomes W, et al. Nocturnal motor activity and light exposure: Objective actigraphy-based marks of melancholic and non-melancholic depressive disorder. Brief report. Psychiatry Res 2017; 258: 587-90.
[http://dx.doi.org/10.1016/j.psychres.2017.08.025] [PMID: 28844556]
[79]
Saeb S, Zhang M, Karr CJ, et al. Mobile phone sensor correlates of depressive symptom severity in daily-life behavior: An exploratory study. J Med Internet Res 2015; 17(7): e175.
[http://dx.doi.org/10.2196/jmir.4273] [PMID: 26180009]
[80]
Dagum P. Digital biomarkers of cognitive function. NPJ Digit Med 2018; 1(1): 10.
[http://dx.doi.org/10.1038/s41746-018-0018-4] [PMID: 31304295]
[81]
Sverdlov O, Curcic J, Hannesdottir K, et al. A study of novel exploratory tools, digital technologies, and central nervous system biomarkers to characterize unipolar depression. Front Psychiatry 2021; 12: 640741.
[http://dx.doi.org/10.3389/fpsyt.2021.640741] [PMID: 34025472]
[82]
Taliaz D, Souery D. A new characterization of mental health disorders using digital behavioral data: Evidence from major depressive disorder. J Clin Med 2021; 10(14): 3109.
[http://dx.doi.org/10.3390/jcm10143109] [PMID: 34300275]
[83]
Zanardi R, Prestifilippo D, Fabbri C, Colombo C, Maron E, Serretti A. Precision psychiatry in clinical practice. Int J Psychiatry Clin Pract 2020; 25(1): 19-27.
[PMID: 32852246]
[84]
Predictix genetics. Predictix® By Taliaz Health LTD Available from : https://predictix.ai/predictix-genetics/
[85]
Taliaz D, Spinrad A, Barzilay R, et al. Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data. Transl Psychiatry 2021; 11(1): 381.
[http://dx.doi.org/10.1038/s41398-021-01488-3] [PMID: 34238923]
[86]
Spinrad A, Darki-Morag S, Taliaz D. Optimizing prediction of response to antidepressant medications using machine learning and environmental data. Eur Psychiatry 2021; 64(S1): S755-5.
[http://dx.doi.org/10.1192/j.eurpsy.2021.2000]
[87]
Spinrad A, Maatoug R, Haddadi N, et al. Impact of a personalized antidepressant prescription using genetics, socio-demographic and clinical data in major depressive disorder patients: A clinical stud Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris. Paris, France: Sorbonne University 2021.

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy